as potential targets for new anti-itch treatments. Some of these agents are already advancing into clinical trials, indicating a growing interest in TRP channel modulation as a therapeutic ...

ATTO-1310 has the potential to achieve a best-in-disease therapeutic profile in pruritic disease with rapid and deep relief of itch, benign safety profile ... This includes ATTO-3712, a first-in-class ...